A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback